ATOMO DIAGNOSTICS LIMITED — Capital/Financing Update 2025

Jul 20, 2025

21 July 2025

==> picture [75 x 72] intentionally omitted <==

ASX Announcement

Successful Placement from Share Purchase Plan Shortfall

SYDNEY Australia, 21 July 2025 – Atomo Diagnostics Limited (ASX: AT1 ) ( Atomo or the Company ), an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market, is pleased to announce that it has placed the shortfall of $727,612.50 from the Share Purchase Plan (“ SPP ”) to a range of sophisticated investors (“ Shortfall Placement ”).

The company originally raised $272,387.50 through its SPP with the allotment of 14,723,685 shares to existing shareholders. Today, a total of 14,054,054 shares were placed to investors who participated in the Shortfall Placement, raising a total of $260,000. The Shortfall Placement was approved by shareholders at the recent Extraordinary General Meeting held on 23 June 2025. The investors will also be issued 14,054,054 Options with an exercise price of $0.04, expiring 24 July 2028, on the same terms as the SPP. It is anticipated that the Shortfall securities will be allotted on Thursday 24 July 2025.

The Shortfall Placement was lead managed by Bay Financial Pty Ltd and GBA Capital Pty Ltd. The joint lead manager fees is 6% of the funds placed. The funds raised will be used to meet the general working capital requirements and funding of its ongoing business objectives.

Managing Director & CEO & Interim Chair, John Kelly, commented:

“ On behalf of the Board of Atomo Diagnostics Limited I wish to thank existing and new shareholders for their participation in the Company’s fund-raising initiatives via the Placement, Share Purchase Plan and Shortfall Placement. This additional capital places the Company in a strong position to move forward with its operational activities. The Company reserves the right to place out the remaining shares from the SPP Shortfall ”.

**~ ENDS ~**

For more information, please contact:

John Kelly

Managing Director & CEO & Interim Chair e. john.kelly@atomodiagnostics.com p. +61 401 922 279

This announcement was authorised by the Board.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 72] intentionally omitted <==

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684